(redirected from Ofirmev)
Also found in: Thesaurus, Medical, Encyclopedia.


 (ə-sē′tə-mĭn′ə-fən, ăs′ə-)
A crystalline compound, C8H9NO2, used in medicine to relieve pain and reduce fever. Also called paracetamol.


(Pharmacology) a US name for paracetamol


(əˌsi təˈmɪn ə fən, ˌæs ɪ tə-)

a crystalline substance, C8H9NO2, used as a headache and pain reliever and to reduce fever.
[1955–60; acet- + amino- + phen (ol)]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.acetaminophen - an analgesic for mild pain but not for inflammationacetaminophen - an analgesic for mild pain but not for inflammation; also used as an antipyretic; (Datril, Tylenol, Panadol, Phenaphen, Tempra, and Anacin III are trademarks of brands of acetaminophen tablets)
analgesic, anodyne, pain pill, painkiller - a medicine used to relieve pain


n acetaminofén m, acetaminofeno, paracetamol m (INN)
References in periodicals archive ?
The Journal cites similar increases for Ofirmev pain injections and Vimovo pain tablets after new companies acquired the rights.
and Canadian rights to Ofirmev in 2006 from Bristol-Myers Squibb Co.
Candence Pharmaceuticals (Nasdaq: CADX) has an early November PDUFA date and expected FDA decision for OFIRMEV (intravenous or IV acetaminophen).
Incline is developing its needle-free system, Ionsys, to deliver painkillers following surgery, while Cadence is trying to obtain regulatory approval for its experimental pain injection, Ofirmev.
These factors were partially offset by higher selling, general and administrative costs and interest expense resulting from the debt associated with the acquisitions of Acthar and OFIRMEV.
Through 2018, market growth attributable to a growing patient population and continued uptake of several branded pain therapies-most notably Mallinckrodt's Ofirmev and Pacira's Exparel in the United States and fast-acting fentanyl formulations across all markets under study-will be tempered by generic erosion of several sales-leading pain therapies, such as Pfizer/Astellas' Celebrex/Celecox.
6% YoY, driven by the inclusion and performance of OFIRMEV, acquired in March 2014; strong performance in base specialty controlled substance generics portfolio; and positive Methylphenidate ER performance.
April 29, 2014 /PRNewswire/ -- Decision Resources Group finds that Mallinckrodt's (formerly Cadence Pharmaceuticals') Ofirmev, the only parenteral formulation of acetaminophen to have reached the U.
The Company also stated that its brand roster will now include OFIRMEV (acetaminophen) injection, which will also help expand Mallinckrodt's services in U.